111In标记PEG化美登素尼妥珠单抗药物偶联物的EGFR阳性肿瘤临床前评价
研究开发了携带PEG6-DM1的尼妥珠单抗抗体药物偶联物(ADC),药物抗体比分别为3.5和7.3,并用111In标记后进行SPECT/CT成像与离体生物分布研究。结果显示PEG6-DM1偶联降低EGFR亲和力但提高内化率,高药物抗体比偶联物体内肿瘤摄取低且清除慢。
要点
- PEG6-DM1偶联数量增加导致EGFR亲和力下降。
- 高药物抗体比ADC内化率最高但肿瘤摄取最低。
- 高药物抗体比ADC血液和全身清除最慢。
核心结论
- 多个PEG6-DM1偶联在体外降低EGFR亲和力,但高内化率可部分抵消该效应。
- 亲和力下降导致高药物抗体比111In-nimotuzumab-PEG6-DM1-High肿瘤摄取低且全身清除慢。
研究设计与样本
- 研究为临床前评价,使用非侵入性小动物SPECT/CT成像和离体生物分布。
- 构建尼妥珠单抗-PEG6-DM1-Low和-High两种免疫偶联物,药物抗体比分别为3.5和7.3。
- 偶联物经DOTA修饰后以111In标记,在正常小鼠和DLD-1肿瘤荷瘤小鼠中评估药代动力学、生物分布和成像特征。
主要发现
- 流式细胞术和生物层干涉术显示PEG6-DM1数量增加时EGFR亲和力呈下降趋势。
- PEG6-DM1 ADC的内化率高于非PEG化ADC,顺序为111In-nimotuzumab-PEG6-DM1-High > Low > 111In-nimotuzumab。
- 111In-nimotuzumab-PEG6-DM1-High的核摄取比111In-nimotuzumab高4.4倍。
- 111In-nimotuzumab-PEG6-DM1-High的血液和全身清除速率最慢。
- DLD-1肿瘤中111In-nimotuzumab摄取与Low相似但显著高于High,且111In-nimotuzumab和Low的肿瘤-背景比值高于High。
关键数值与推荐
- 药物抗体比:nimotuzumab-PEG6-DM1-Low为3.5,High为7.3。
- 核摄取:111In-nimotuzumab-PEG6-DM1-High比111In-nimotuzumab高4.4倍。
临床怎么用
- PEG化ADC的体外亲和力与内化率需综合评估,不可仅凭亲和力预测体内行为。
- 高药物抗体比可能因亲和力下降而降低肿瘤摄取并延缓清除,需在剂量设计中考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epidermal growth factor receptor I (EGFR) is overexpressed in most cancers of epithelial origin. Antibody drug conjugates (ADCs) with PEGylated-maytansine (PEG-DM1) show promise in vitro and in vivo. However, in vivo biodistribution data for ADCs with PEG-DM1 have not been reported. Development of methods to understand the real-time in vivo behavior of these ADCs is needed to move these compounds to the clinic. Methods: Here we have used noninvasive small-animal SPECT/CT imaging and ex vivo biodistribution to understand the in vivo behavior of PEG6-DM1 ADCs. We developed nimotuzumab ADCs conjugated to PEG6-DM1. We generated immunoconjugates with low (nimotuzumab-PEG6-DM1-Low) and high (nimotuzumab-PEG6-DM1-High) drug-to-antibody ratios. The drug-to-antibody of nimotuzumab-PEG6-DM1-Low and nimotuzumab-PEG6-DM1-High was 3.5 and 7.3, respectively. Quality control was performed using ultraviolet spectrophotometry, size-exclusion high-performance liquid chromatography, bioanalyzer, biolayer interferometry, and flow cytometry in EGFR-positive DLD-1 cells. These immunoconjugates were conjugated with DOTA and radiolabeled with 111In. The in vitro binding and internalization rates of 111In-nimotuzumab, 111In-nimotuzumab-PEG6-DM1-Low, and 111In-nimotuzumab-PEG6-DM1-High were characterized. Furthermore, the pharmacokinetics, biodistribution, and imaging characteristics were evaluated in normal and DLD-1 tumor-bearing mice. Results: Flow cytometry and biolayer interferometry showed a trend toward decreasing EGFR affinity with increasing number of PEG6-DM1 on the antibody. Despite the lower overall cellular binding of the PEG6-DM1 radioimmunoconjugates, internalization was higher for PEG6-DM1 ADCs than for the non-PEGylated ADC in the following order: 111In-nimotuzumab-PEG6-DM1-High > 111In-nimotuzumab-PEG6-DM1-Low > 111In-nimotuzumab. Nuclear uptake of 111In-nimotuzumab-PEG6-DM1-High was 4.4-fold higher than 111In-nimotuzumab. Pharmacokinetics and biodistribution showed that 111In-nimotuzumab-PEG6-DM1-High had the slowest blood and whole-body clearance rate. Uptake in DLD-1 tumors of 111In-nimotuzumab was similar to 111In-nimotuzumab-PEG6-DM1-Low but was significantly higher than for 111In-nimotuzumab-PEG6-DM1-High. Tumor-to-background ratios for 111In-nimotuzumab and 111In-nimotuzumab-PEG6-DM1-Low were higher than for 111In-nimotuzumab-PEG6-DM1-High. Conclusion: The results show that conjugation of multiple PEG6-DM1 reduces the affinity for EGFR in vitro. However, the reduced affinity is counteracted by the high internalization rate of constructs with PEG6-DM1 ADCs in vitro. The decreased affinity resulted in low tumor uptake of 111In-nimotuzumab-PEG6-DM1-High, with a slow overall whole-body clearance rate. These data provide insights for evaluating the pharmacokinetics and normal -tissue toxicity and in determining dosing rate of PEGylated ADCs.
引用
- Hartimath SV, Alizadeh E, Solomon VR, et al. Preclinical Evaluation of 111In-Labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-Positive Cancer Models. J Nucl Med. 2019. PMID: 30655327. doi:10.2967/jnumed.118.220095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。